Blog
RSS FeedPosted by Michael Wonder on 17 Aug 2020
Janssen and others have appealed NICE's decision to reject abiraterone acetate for patients with for high risk hormone-sensitive metastatic prostate cancer
17 August 2020 - The appeal panel will convene on 3 September and 4 September to hear oral representations from the ...
Posted by Michael Wonder on 17 Aug 2020
NICE publishes guidance on Astellas' Xospata
17 August 2020 - The National Institute for Health and Care Excellence has now published final guidance backing NHS use ...
Posted by Michael Wonder on 13 Aug 2020
NICE recommends Adcetris for first-line use for patients with a rare form of non-Hodgkin's lymphoma
12 August 2020 - NICE has published its final guidance on the use of brentuximab vedotin in combination with chemotherapy ...
Posted by Michael Wonder on 06 Aug 2020
NICE supports use of new medicine for patients with malignant disease
5 August 2020 - Treosulphan is used as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation. ...
Posted by Michael Wonder on 05 Aug 2020
NICE publishes draft guidance on the use of a topical gel by patients with a rare cancer
5 August 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using chlormethine gel ...
Posted by Michael Wonder on 31 Jul 2020
NICE recommends Bavencio (avelumab) in combination with axitinib for first-line treatment of adult patients with advanced renal cell carcinoma
31 July 2020 - This is the first combination of an immunotherapy with a targeted antiangiogenic therapy to be recommended ...
Posted by Michael Wonder on 30 Jul 2020
NICE rejects NHS funding for Kyowa Kirin's Poteligeo
30 July 2020 - NICE is not recommending NHS funding for Kyowa Kirin's Poteligeo (mogamulizumab) as a treatment for mycosis ...
Posted by Michael Wonder on 20 Jul 2020
Developing NICE guidelines
17 July 2020 - NICE has published interim process and methods for guidelines developed in response to health and social ...
Posted by Michael Wonder on 19 Jul 2020
US purchases world stocks of remdesivir: why the rest of the world should be glad to be at the back of the queue
18 July 2020 - The remdesivir story may actually be good news for the rest of the world. ...
Posted by Michael Wonder on 17 Jul 2020
NICE backing for Astellas' Xospata
17 July 2020 - NICE has recommended use of Astellas' Xospata (gilteritinib) for adults with relapsed or refractory FLT3 mutation-positive ...
Posted by Michael Wonder on 15 Jul 2020
The impact of managed entry agreements on pharmaceutical prices
6 July 2020 - Managed entry agreements have been used for several years, with the aim of curbing the growth of ...
Posted by Michael Wonder on 14 Jul 2020
NICE partners with Flatiron Health to develop real world evidence research methodologies
14 July 2020 - Collaboration will help NICE expand use of real world data in service of better outcomes for UK ...
Posted by Michael Wonder on 13 Jul 2020
Are high‐cost drug funding mechanisms fit for purpose? A retrospective study of individual funding requests in an NHS tertiary hospital
13 July 2020 - This paper reports on a retrospective study of individual funding request submissions from a large tertiary hospital ...
Posted by Michael Wonder on 12 Jul 2020
Real world evidence use in assessments of cancer drugs by NICE
10 July 2020 - Single technology assessments published by NICE from April 2011 to October 2018 that evaluated cancer treatments were ...
Posted by Michael Wonder on 12 Jul 2020
Why it’s time to abandon the ICER
10 July 2020 - The incremental cost-effectiveness ratio (ICER) is the most commonly reported summary measure for economic evaluations of health ...